With your permission, I'll go first. Thank you for asking such detailed questions. I'm not convinced that the process is not working. I don't think that has been proven yet. One of the reasons why the program hasn't been used thus far is the price of generic products in Canada. You can add that to your list of reasons. However, I'd like to explain that the act isn't quite that complex. There are certain requirements: where does the request originate, what quantity of product is being sought, who will be using them and for how long. It doesn't seem all that complicated to me.
Unfortunately, to date, generic companies haven't proceeded to step two, that is to test the system. If we want assurances that new HIV drugs are effective, we need to do some research. We're trying to strike a balance between protecting intellectual property and providing access to drugs. One does not preclude the other. First we need to let countries know that we have legislation on the books. That's why I visited 25 embassies to explain the act. We can start by letting the public know that this act does exist. In addition, we have documented proof that our R&D companies have partnered a great deal with other countries and with NGOs, the non-governmental organizations. We operate in the field successful programs providing access to drugs, clinics, and health, education and professional training systems. In my view, we need to take a comprehensive approach. We can continue to support the act while advocating that Canada take a comprehensive approach to this issue.
Summing up, I hope that we will be successful and that very soon, we will have a product that passes the test from every angle, a product that will allow for the system to be used while other countries continue to develop access programs.